ATE435209T1 - Verfahren zur herstellung von montelukast-natrium - Google Patents

Verfahren zur herstellung von montelukast-natrium

Info

Publication number
ATE435209T1
ATE435209T1 AT05739023T AT05739023T ATE435209T1 AT E435209 T1 ATE435209 T1 AT E435209T1 AT 05739023 T AT05739023 T AT 05739023T AT 05739023 T AT05739023 T AT 05739023T AT E435209 T1 ATE435209 T1 AT E435209T1
Authority
AT
Austria
Prior art keywords
montelukast sodium
producing montelukast
producing
sodium
present
Prior art date
Application number
AT05739023T
Other languages
English (en)
Inventor
Evgeny Shapiro
Ronit Yahalomi
Valerie Niddam-Hildesheim
Greta Sterimbaum
Kobi Chen
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Application granted granted Critical
Publication of ATE435209T1 publication Critical patent/ATE435209T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Saccharide Compounds (AREA)
AT05739023T 2004-04-21 2005-04-21 Verfahren zur herstellung von montelukast-natrium ATE435209T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56450404P 2004-04-21 2004-04-21
US58223704P 2004-06-22 2004-06-22
PCT/US2005/014011 WO2005105751A1 (en) 2004-04-21 2005-04-21 Processes for preparing montelukast sodium

Publications (1)

Publication Number Publication Date
ATE435209T1 true ATE435209T1 (de) 2009-07-15

Family

ID=34966501

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05739023T ATE435209T1 (de) 2004-04-21 2005-04-21 Verfahren zur herstellung von montelukast-natrium

Country Status (11)

Country Link
US (1) US7547787B2 (de)
EP (1) EP1646612B1 (de)
JP (1) JP2007532686A (de)
KR (1) KR100815670B1 (de)
AT (1) ATE435209T1 (de)
CA (1) CA2563776A1 (de)
DE (1) DE602005015174D1 (de)
ES (1) ES2327762T3 (de)
IL (1) IL176142A (de)
MX (1) MXPA06012220A (de)
WO (1) WO2005105751A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005025863A1 (ja) * 2003-09-09 2005-03-24 Mitsubishi Polyester Film Corporation 離型シート及び粘着体
US20050187244A1 (en) * 2004-01-30 2005-08-25 Entire Interest. Montelukast sodium polymorphs
CA2554572A1 (en) * 2004-01-30 2005-08-18 Teva Pharmaceutical Industries Ltd. Montelukast free acid polymorphs
KR100899585B1 (ko) * 2005-07-05 2009-05-27 테바 파마슈티컬 인더스트리즈 리미티드 몬테루카스트의 정제
US20080214823A1 (en) * 2005-07-20 2008-09-04 Dr. Reddy's Laboratories Ltd. Preparation of Montelukast
US7528254B2 (en) 2006-02-27 2009-05-05 Chemagis Ltd. Process for preparing montelukast and salts thereof
US20090326232A1 (en) * 2006-06-26 2009-12-31 Uttam Kumar Ray Process for the Preparation of Leukotriene Receptor Antagonist (Montelukast Sodium)
EP1886998A1 (de) 2006-08-09 2008-02-13 Esteve Quimica, S.A. Verfahren zur Reinigung von Montelukast und dessen Aminesalzen
US7700776B2 (en) 2006-10-24 2010-04-20 Formosa Laboratories, Inc. Compounds and preparation for montelukast sodium
KR100774088B1 (ko) 2006-12-14 2007-11-06 한미약품 주식회사 몬테루카스트의 제조방법 및 이에 사용되는 중간체
CZ302238B6 (cs) * 2007-01-09 2011-01-05 Zentiva, A. S. Zpusob prípravy montelukastu
US20080188664A1 (en) * 2007-01-15 2008-08-07 Chemagis Ltd. Process for preparing montelukast sodium containing controlled levels of impurities
CZ302518B6 (cs) * 2007-07-09 2011-06-29 Zentiva, A. S. Zpusob izolace a cištení montelukastu
ATE547513T1 (de) 2007-09-28 2012-03-15 Codexis Inc Ketoreduktase-polypeptide und verwendungen davon
KR101072896B1 (ko) * 2007-10-09 2011-10-17 한미홀딩스 주식회사 이온성 액체 매개체를 이용한 몬테루카스트산의 제조 방법
DE102007061630B4 (de) 2007-12-20 2013-07-04 Formosa Laboratories, Inc. Neue Verbindungen und Herstellung von Montelukast-Natrium
WO2009138993A1 (en) * 2008-05-13 2009-11-19 Macleods Pharmaceuticals Limited A process for preparation of montelukast sodium salt
ES2605473T3 (es) * 2008-05-26 2017-03-14 Laurus Labs Private Limited Un procedimiento mejorado para la preparación de Montelukast y sus sales
KR101123292B1 (ko) 2008-09-26 2012-03-19 주식회사 엘지생명과학 몬테루카스트 나트륨염의 제조방법
WO2011004298A1 (en) 2009-07-09 2011-01-13 Alembic Limited Montelukast hexamethylenediamine salt and its use for the preparation of montelukast sodium
EP2552892A1 (de) 2010-03-31 2013-02-06 KRKA, D.D., Novo Mesto Effiziente synthese zur herstellung von montelukast und neue kristalline form von zwischenprodukten darin
HUP1000425A2 (en) 2010-08-11 2012-03-28 Richter Gedeon Nyrt Process for the production of montelukast sodium
US8471030B2 (en) 2010-12-06 2013-06-25 Orochem Technologies Inc. Purification of montelukast using simulated moving bed
CN105541711B (zh) * 2016-02-22 2018-06-19 齐鲁天和惠世制药有限公司 一种孟鲁司特的制备方法
CN105541710B (zh) * 2016-02-22 2018-06-19 齐鲁天和惠世制药有限公司 一种孟鲁司特的合成方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856322A (en) 1990-10-12 1999-01-05 Merck Frosst Canada, Inc. Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
EP0480716A1 (de) 1990-10-12 1992-04-15 Merck Frosst Canada Inc. Gesättigte Hydroxyalkylchinolinsäuren zur Verwendung als Leukotrien-Antagonisten
DK0480717T3 (da) * 1990-10-12 1999-02-08 Merck Frosst Canada Inc Umættede hydroxyalkylquinolinsyrer som leukotrienantagonister
US5565473A (en) 1990-10-12 1996-10-15 Merck Frosst Canada, Inc. Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
IE920499A1 (en) * 1991-02-21 1992-08-26 Merck Frosst Canada Inc Quinoline-containing ketoacids as leukotriene antagonists
TW448160B (en) 1993-12-28 2001-08-01 Merck & Co Inc Novel dicyclohexylamine salt and process for the preparation of leukotriene antagonists
US5523477A (en) 1995-01-23 1996-06-04 Merck & Co., Inc. Process for the preparation of 1-(thiomethyl)-cyclopropaneacetic acid
US5750539A (en) 1995-06-07 1998-05-12 Merck Frosst Canada Heteroaryl diol acids as leukotriene antagonists
US5952347A (en) 1997-03-13 1999-09-14 Merck & Co., Inc. Quinoline leukotriene antagonists
GB9812413D0 (en) 1998-06-10 1998-08-05 Glaxo Group Ltd Compound and its use
FI104718B (fi) 1998-06-18 2000-03-31 Orion Yhtymae Oyj [[4-(2-atsido-3-metyyli-5-oksotetrahydrofuran-2-yyli)fenyyli]hydratsono]propaanidinitriili käytettäväksi referenssiaineena levosimendaanierien analyysissä
US6716452B1 (en) * 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
WO2003066598A1 (en) 2002-02-07 2003-08-14 Dr. Reddy's Laboratories Ltd. Novel anhydrous amorphous forms of montelukast sodium salt
US20050107612A1 (en) 2002-12-30 2005-05-19 Dr. Reddy's Laboratories Limited Process for preparation of montelukast and its salts
EP1633357A4 (de) 2003-04-15 2010-02-10 Merck & Co Inc Polymorphe form von montelukast-natrium
CA2528228C (en) 2003-06-06 2011-09-20 Morepen Laboratories Limited A method for the preparation of montelukast acid and sodium salt thereof in amorphous form
US7553853B2 (en) 2003-10-10 2009-06-30 Synthon Bv Solid-state montelukast
EP1709001A2 (de) 2004-01-28 2006-10-11 Pliva Istrazivanje i Razvoj d.o.o. Feste formen von montelukastsäure
CA2554572A1 (en) 2004-01-30 2005-08-18 Teva Pharmaceutical Industries Ltd. Montelukast free acid polymorphs
JP2007520546A (ja) 2004-02-03 2007-07-26 ケマジス リミティド モンテルカストナトリウムの安定な非晶質性形態
US7189853B2 (en) 2004-04-15 2007-03-13 Dr. Reddy's Laboratories Limited Process for the preparation of [R-(E)-1-[[[1-[3-[2-[7-chloro-2-quinolinyl]ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetic acid (Montelukast) and its pharmaceutically acceptable salts
WO2006008751A2 (en) 2004-07-19 2006-01-26 Matrix Laboratories Ltd Process for the preparation of montelukast and its salts
PL205637B1 (pl) 2004-10-22 2010-05-31 Inst Farmaceutyczny Sposób wytwarzania kwasu (R,E)-(1-{1-{3-[2-(7-chlorochinolin-2-ylo)etenylo]fenylo}-3-[2-(1-hydroksy-1-metyloetylo)fenylo] propylosulfanylometylo}cyklopropylo)octowego i/lub jego farmaceutycznie dopuszczalnych soli
EP1817289A1 (de) 2004-11-30 2007-08-15 Medichem, S.A. Neues verfahren zur herstellung einesleukotrienantagonisten
KR100899585B1 (ko) 2005-07-05 2009-05-27 테바 파마슈티컬 인더스트리즈 리미티드 몬테루카스트의 정제

Also Published As

Publication number Publication date
IL176142A0 (en) 2006-10-05
CA2563776A1 (en) 2005-11-10
JP2007532686A (ja) 2007-11-15
US7547787B2 (en) 2009-06-16
DE602005015174D1 (de) 2009-08-13
KR20070004114A (ko) 2007-01-05
IL176142A (en) 2010-12-30
KR100815670B1 (ko) 2008-03-20
ES2327762T3 (es) 2009-11-03
WO2005105751A1 (en) 2005-11-10
US20050256156A1 (en) 2005-11-17
EP1646612B1 (de) 2009-07-01
MXPA06012220A (es) 2007-07-18
EP1646612A1 (de) 2006-04-19

Similar Documents

Publication Publication Date Title
ATE435209T1 (de) Verfahren zur herstellung von montelukast-natrium
ATE425136T1 (de) Verfahren zur herstellung substituierter 3-aryl- butyl-aminverbindungen
DE502004009763D1 (de) Verfahren zur herstellung von 1-buten
ATE408604T1 (de) Verfahren zur herstellung von 1-alkyl-3- phenyluracilen
DE502006000218D1 (de) Verfahren zur Herstellung von SiOC-verknüpften, linearen Polydialkylsiloxan-Polyoxyalkylen-Blockcopolymeren
DE602005016292D1 (de) Verfahren zur herstellung von glatiramer
ATE408609T1 (de) Verfahren zur herstellung von n-phenylpyrazol-1- carboxamiden
ATE516816T1 (de) Verfahren zur herstellung von impfstoffen
ATE443038T1 (de) Verfahren zur herstellung von cinacalcet hydrochlorid
DE502005010038D1 (de) Verfahren zur herstellung von 3-pentennitril
DE602006015090D1 (de) Verfahren zur herstellung von gezielt durchlässigen laminaten
DE602004020895D1 (de) Verfahren zur herstellung von kohlenstoffnanospulen
DE60302139D1 (de) Verfahren zur herstellung von aripiprazole
ATE516290T1 (de) Verfahren zur herstellung von buprenorphin und derivaten von buprenorphin
ATE376997T1 (de) Verfahren zur herstellung von 1,4- diphenylazetidinon-derivaten
DE502006006803D1 (de) Verfahren zur herstellung von leder
DE502005000428D1 (de) Verfahren zur Herstellung von 1,2-Diaminocyclohexan-Platin(II)-Komplexen
DE602005021110D1 (de) Verfahren zur herstellung von n-piperidino-1,5-diphenylpyrazol-3-carboxamid-derivaten
ATE444303T1 (de) Verfahren zur herstellung von ferrisuccinylcasein
DE502005007702D1 (de) Verfahren zur herstellung von terrylen-3,4:11,12-t
DE502006004187D1 (de) Verfahren zur herstellung von diorganopolysiloxanen
ATE405374T1 (de) Verfahren zur herstellung von brillengläsern
ATE549314T1 (de) Verfahren zur herstellung von 4-aminochinazolinen
DE502004002810D1 (de) Verfahren zur herstellung von copolymerisaten
ATE554064T1 (de) Verfahren zur herstellung von entacapon

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties